Cargando…
Compliance with the Updated BASHH Recurrent Vulvovaginal Candidiasis Guidelines Improves Patient Outcomes
Recurrent vulvovaginal candidiasis (RVVC) is a debilitating, chronic condition that affects over 138 million (6%) women of reproductive age annually. We performed a retrospective audit of RVVC referrals to our tertiary care Candida clinic to evaluate the impact of the significantly updated British A...
Autores principales: | Brown, Lottie, Chamula, Mathilde, Weinberg, Sharon, Jbueen, Frakinda, Rautemaa-Richardson, Riina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503580/ https://www.ncbi.nlm.nih.gov/pubmed/36135648 http://dx.doi.org/10.3390/jof8090924 |
Ejemplares similares
-
Distinct host immune responses in recurrent vulvovaginal candidiasis and vulvovaginal candidiasis
por: Ge, Gai, et al.
Publicado: (2022) -
Recurrent Vulvovaginal Candidiasis: An Immunological Perspective
por: Rosati, Diletta, et al.
Publicado: (2020) -
Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp
por: Grant, Leah M., et al.
Publicado: (2022) -
Insights and advances in recurrent vulvovaginal candidiasis
por: San Juan Galán, Javier, et al.
Publicado: (2023) -
BASHH updated position statement on doxycycline as prophylaxis for sexually transmitted infections
por: Kohli, Manik, et al.
Publicado: (2022)